OTTAWA, Canada–(BUSINESS WIRE)–Eureka 93 Inc. (CSE: ERKA, “Eureka93”) announced today that the Board of Directors, after having reviewed strategic alternatives, resolved on February 14, 2020 to file a Notice of Intention to Make a Proposal (“NOI”) under Section 50.4(1) of the Bankruptcy and Insolvency Act, R.S.C 1985, c.B-3, as amended (BIA) for each of Eureka 93 Inc., Artiva Inc., LiveWell Foods Canada Inc., and Vitality CBD Natural Health Products Inc. The Ontario Superior Court proposal motion hearing date was held on March 6, 2020, and the Order was signed and issued by the judge on March 12, 2020.

As part of Eureka 93’s continuous disclosure requirements, this represents a material change effective February 14, 2020 wherein the listed company and certain Canadian related entities filed for court protection to undertake to prepare a proposal under the BIA, as noted below:

Eureka 93 Inc. et al (the “Company” or the “Debtor’s”)

​On February 14, 2020 (the “Filing Date”), Eureka 93 Inc., Artiva Inc., LiveWell Foods Canada Inc., and Vitality CBD Natural Health Products Inc. (the “Related Entities”) each filed a Notice of Intention to Make a Proposal (“NOI”) under Section 50.4(1) of the Bankruptcy and Insolvency Act, R.S.C 1985, c.B-3, as amended (“BIA”). Deloitte was appointed as Proposal Trustee (“Deloitte” or the “Trustee”) under each NOI.

The Proposal Motion Hearing was heard by the Ontario Superior Court of Justice (the “Court”) on March 6, 2020, and the Court approved the Proposal process to proceed under Section 50.4(1) of the BIA.

Pursuant to Section 69(1) of the BIA, the effect of filing an NOI is an automatic stay of proceedings (the “Stay”) against all creditors from continuing or commencing any actions against the Company. The Company had 30 days to file a Proposal to its creditors, or to seek an extension of the time from the Court to file a Proposal. The Company received an extension from the Court to file a Proposal to its creditors by April 28, 2020, and can seek an extension of time if required.

The Company is continuing to operate and maintain its business in the ordinary course during the NOI proceedings and the Trustee is required to monitor the Company’s business and affairs during the Stay and report any material adverse changes to the Office of the Superintendent of Bankruptcy and the Court.

The Company has negotiated for new financing called “debtor-in-possession” or “DIP” financing to provide additional liquidity during the NOI proceedings for which it has sought and received Court Order approval on March 12, 2020. The Company has also sought and received Court approval for an administrative consolidation of its proposal proceedings with the Related Entities.

The NOI generally prohibits the Company from paying for goods and services that were received on or before the Filing Date and if you are owed monies for goods and services supplied on or before the Filing date, you will have an opportunity to file a Proof of Claim once a claims process is established. As part of the Proof of Claim process, creditors and suppliers at that time should provide invoices to the Trustee for goods and services delivered up to and including the Filing Date, and separate invoices for all goods and services delivered after the Filing Date.

Creditor and contributory ranking on a Debtor’s NOI under the BIA rank in the following order: Creditor claims have priority over shareholder claims. Secured creditors rank ahead of preferred and unsecured creditors other than for certain claims that are given priority under statute.

Updates and information related to the NOI proceedings will be posted on Deloitte’s website at www.insolvencies.deloitte.ca under the link entitled “Eureka 93 Inc. et al”. If you have any additional questions regarding this matter, please contact Deloitte Restructuring Inc. attention: Stacey Greenbaum, CPA, CA. Telephone: (416) 874-4320 Fax: (416) 601-6690. Email: sgreenbaum@deloitte.ca

Deloitte Restructuring Inc.

8 Adelaide Street West, Suite #200

Toronto, ON M5J 0A9. Canada

Attention: Hartley Bricks, MBA, CPA, CA, CIRP, LIT

Telephone: (416) 775-7326

Fax: (416) 601-6690

Email: hbricks@deloitte.ca

or

Attention: Stacey Greenbaum, CPA, CA

Telephone: (416) 874-4320

Fax: (416) 601-6690

Email: sgreenbaum@deloitte.ca

Further information will be posted on Deloitte’s website at www.insolvencies.deloitte.ca under the link entitled “Eureka 93 Inc. et al”.

The Board of Eureka 93 Inc. plans to be in a position to complete residual restructuring matters over the coming weeks and months, and begin to focus on development in Artiva Inc. and the Cannabis license.

About Eureka93

Eureka 93 Inc. (Eureka93) is an integrated life sciences company focused on the cultivation, extraction, and distribution of cannabis and hemp-derived cannabidiol (CBD) through it’s Health Canada licensed Artiva facility in Ottawa, Canada. For more information, please visit: Eureka93.com